• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SLA
Click for more information
1.12% $4.50

SILK LASER AUSTRALIA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SLAMarket Update06/07/10
BPO +Solagran and BioProspect Development Agreement29/06/10
BPO +Bioeffectives Project with BioProspect LimitedPRICE SENSITIVE28/06/10
SLARopren brought the life backPRICE SENSITIVE24/06/10
SLAMarket UpdatePRICE SENSITIVE06/05/10
SLAAppendix 3B03/05/10
SLAAppendix 4C - quarterlyPRICE SENSITIVE29/04/10
SLAOptions Exercise and Appendix 3Y28/04/10
SLARussian Market UpdatePRICE SENSITIVE21/04/10
BPO +Change in substantial holding from SLA15/03/10
SLAMarket UpdatePRICE SENSITIVE12/03/10
SLARussian Sales Update09/03/10
SLAHalf Yearly Report and AccountsPRICE SENSITIVE26/02/10
BPO +BioProspect and Solagran agreement to commercialisePRICE SENSITIVE25/02/10
SLAResponse to an ASX re 4C QueryPRICE SENSITIVE05/02/10
SLARussian Market UpdatePRICE SENSITIVE05/02/10
SLATrading HaltPRICE SENSITIVE03/02/10
SLAAppendix 4CPRICE SENSITIVE29/01/10
SLAAppendix 3B21/12/09
SLAExercise of Options / Appendix 3Y - Dr Soultanov18/12/09
SLAAppendix 3Y11/12/09
SLAMeeting with President's Representative11/12/09
SLAResponse to ASX Price QueryPRICE SENSITIVE10/12/09
SLAShareholders Presentation09/12/09
SLARussia Update26/11/09
SLAResults of Meeting23/11/09
SLAShareholders Information Session Wednesday, 9 Dec 200920/11/09
SLAProgress Report USAPRICE SENSITIVE19/11/09
SLARussian President's Visit16/11/09
SLAAppendix 3B13/11/09
SLARopren Has Many Answers says Dr E. Golovanova12/11/09
SLAResponse to ASX Price QueryPRICE SENSITIVE04/11/09
SLAAppendix 4CPRICE SENSITIVE30/10/09
SLAAppointment of Chief Financial Officer29/10/09
SLARussian Sales Entity Established22/10/09
SLANotice of General Meeting/Proxy Form21/10/09
SLAAnnual Report to shareholders21/10/09
SLAFinal Call of $0.10 per Contributing Share14/10/09
SLAFinal Call of $0.10 per Contributing SharePRICE SENSITIVE12/10/09
SLAMessage from the Chairman02/10/09
SLAAnnual Report to shareholders01/10/09
SLAResponse to an ASX Price QueryPRICE SENSITIVE10/09/09
SLAPreliminary Final ReportPRICE SENSITIVE31/08/09
SLAAppendix 3B17/08/09
SLAClinical Trial Registration St Vincent's Hospital MelbournePRICE SENSITIVE03/08/09
SLAAppendix 4C - quarterlyPRICE SENSITIVE03/08/09
SLAUpdated Initial Substantial Holder Notice - Ace Aim Pte Ltd29/07/09
SLASection 708A Notice29/07/09
SLAAppendix 3B29/07/09
SLABecoming a substantial holder28/07/09
SLAInitial Director's Interest Notice28/07/09
SLACommencement of Strategic Partnership with Salim Group28/07/09
SLAAppendix 3B27/07/09
SLASolagran Attracts Stretegic PartnerPRICE SENSITIVE20/07/09
SLASLA - Response to an ASX Price QueryPRICE SENSITIVE20/07/09
SLATrading Halt Request16/07/09
SLATrading HaltPRICE SENSITIVE16/07/09
SLAPatent Update14/07/09
SLAAppointment of Company Secretary09/07/09
SLARegulatory Approval in Malaysia for Bioeffective APRICE SENSITIVE08/07/09
SLAFinal Director's Interest Notice06/07/09
SLADirector Appointment/Resignation01/07/09
SLABioeffectives Skincare Joint VenturePRICE SENSITIVE07/05/09
SLAAppendix 4CPRICE SENSITIVE30/04/09
SLADue Diligence Review April 200927/04/09
SLAVisit of Delegation Revised27/04/09
SLAVisit of Delegation24/04/09
SLAAppendix 3Z06/04/09
SLAMarket Update01/04/09
SLAAllotment for Contributing Shares (SLACF)17/03/09
SLAStatus Report - Bioeffective RPRICE SENSITIVE16/03/09
SLAAllotment for Contributing Shares13/03/09
SLATimetable11/03/09
SLAAppendix 3B10/03/09
SLAAmended Appendix 4D02/03/09
SLAAppendix 4DPRICE SENSITIVE02/03/09
SLAAppendix 3B and Status Report27/02/09
SLAAppendix 3X23/02/09
SLAAppointment of Non-Executive Director23/02/09
SLAFinal Call on Contributing Shares16/02/09
SLAAppendix 3Z13/02/09
SLAAppendix 3X x 212/02/09
SLAGeneral Information12/02/09
SLAChanges to the Board of Directors06/02/09
SLAEntitlement IssuePRICE SENSITIVE30/01/09
SLAAppendix 4CPRICE SENSITIVE30/01/09
SLAFinal Call of $0.05 per Contributing Share21/01/09
SLAFinal Call of $0.05 per Contributing SharePRICE SENSITIVE15/01/09
SLAAppendix 3Y12/01/09
SLAAppendix 3Y08/01/09
SLAEntitlement Issue02/01/09
SLARetirement of Director15/12/08
SLANon-Renounceable Pro-Rata Rights Issue11/12/08
SLAAppendix 3Z05/12/08
SLAAppendix 3B03/12/08
SLAResults of Annual General Meeting01/12/08
SLAPresentation to Annual General Meeting of Shareholders28/11/08
SLAMiddle Eastern and Asian Distribution AgreementsPRICE SENSITIVE26/11/08
SLANon-Renounceable Pro-Rata Rights Issue - Revised TermsPRICE SENSITIVE25/11/08
SLAAppendix 3Y25/11/08
SLAMarket Update
06/07/10
BPO +Solagran and BioProspect Development Agreement
29/06/10
BPO +Bioeffectives Project with BioProspect Limited
28/06/10PRICE SENSITIVE
SLARopren brought the life back
24/06/10PRICE SENSITIVE
SLAMarket Update
06/05/10PRICE SENSITIVE
SLAAppendix 3B
03/05/10
SLAAppendix 4C - quarterly
29/04/10PRICE SENSITIVE
SLAOptions Exercise and Appendix 3Y
28/04/10
SLARussian Market Update
21/04/10PRICE SENSITIVE
BPO +Change in substantial holding from SLA
15/03/10
SLAMarket Update
12/03/10PRICE SENSITIVE
SLARussian Sales Update
09/03/10
SLAHalf Yearly Report and Accounts
26/02/10PRICE SENSITIVE
BPO +BioProspect and Solagran agreement to commercialise
25/02/10PRICE SENSITIVE
SLAResponse to an ASX re 4C Query
05/02/10PRICE SENSITIVE
SLARussian Market Update
05/02/10PRICE SENSITIVE
SLATrading Halt
03/02/10PRICE SENSITIVE
SLAAppendix 4C
29/01/10PRICE SENSITIVE
SLAAppendix 3B
21/12/09
SLAExercise of Options / Appendix 3Y - Dr Soultanov
18/12/09
SLAAppendix 3Y
11/12/09
SLAMeeting with President's Representative
11/12/09
SLAResponse to ASX Price Query
10/12/09PRICE SENSITIVE
SLAShareholders Presentation
09/12/09
SLARussia Update
26/11/09
SLAResults of Meeting
23/11/09
SLAShareholders Information Session Wednesday, 9 Dec 2009
20/11/09
SLAProgress Report USA
19/11/09PRICE SENSITIVE
SLARussian President's Visit
16/11/09
SLAAppendix 3B
13/11/09
SLARopren Has Many Answers says Dr E. Golovanova
12/11/09
SLAResponse to ASX Price Query
04/11/09PRICE SENSITIVE
SLAAppendix 4C
30/10/09PRICE SENSITIVE
SLAAppointment of Chief Financial Officer
29/10/09
SLARussian Sales Entity Established
22/10/09
SLANotice of General Meeting/Proxy Form
21/10/09
SLAAnnual Report to shareholders
21/10/09
SLAFinal Call of $0.10 per Contributing Share
14/10/09
SLAFinal Call of $0.10 per Contributing Share
12/10/09PRICE SENSITIVE
SLAMessage from the Chairman
02/10/09
SLAAnnual Report to shareholders
01/10/09
SLAResponse to an ASX Price Query
10/09/09PRICE SENSITIVE
SLAPreliminary Final Report
31/08/09PRICE SENSITIVE
SLAAppendix 3B
17/08/09
SLAClinical Trial Registration St Vincent's Hospital Melbourne
03/08/09PRICE SENSITIVE
SLAAppendix 4C - quarterly
03/08/09PRICE SENSITIVE
SLAUpdated Initial Substantial Holder Notice - Ace Aim Pte Ltd
29/07/09
SLASection 708A Notice
29/07/09
SLAAppendix 3B
29/07/09
SLABecoming a substantial holder
28/07/09
SLAInitial Director's Interest Notice
28/07/09
SLACommencement of Strategic Partnership with Salim Group
28/07/09
SLAAppendix 3B
27/07/09
SLASolagran Attracts Stretegic Partner
20/07/09PRICE SENSITIVE
SLASLA - Response to an ASX Price Query
20/07/09PRICE SENSITIVE
SLATrading Halt Request
16/07/09
SLATrading Halt
16/07/09PRICE SENSITIVE
SLAPatent Update
14/07/09
SLAAppointment of Company Secretary
09/07/09
SLARegulatory Approval in Malaysia for Bioeffective A
08/07/09PRICE SENSITIVE
SLAFinal Director's Interest Notice
06/07/09
SLADirector Appointment/Resignation
01/07/09
SLABioeffectives Skincare Joint Venture
07/05/09PRICE SENSITIVE
SLAAppendix 4C
30/04/09PRICE SENSITIVE
SLADue Diligence Review April 2009
27/04/09
SLAVisit of Delegation Revised
27/04/09
SLAVisit of Delegation
24/04/09
SLAAppendix 3Z
06/04/09
SLAMarket Update
01/04/09
SLAAllotment for Contributing Shares (SLACF)
17/03/09
SLAStatus Report - Bioeffective R
16/03/09PRICE SENSITIVE
SLAAllotment for Contributing Shares
13/03/09
SLATimetable
11/03/09
SLAAppendix 3B
10/03/09
SLAAmended Appendix 4D
02/03/09
SLAAppendix 4D
02/03/09PRICE SENSITIVE
SLAAppendix 3B and Status Report
27/02/09
SLAAppendix 3X
23/02/09
SLAAppointment of Non-Executive Director
23/02/09
SLAFinal Call on Contributing Shares
16/02/09
SLAAppendix 3Z
13/02/09
SLAAppendix 3X x 2
12/02/09
SLAGeneral Information
12/02/09
SLAChanges to the Board of Directors
06/02/09
SLAEntitlement Issue
30/01/09PRICE SENSITIVE
SLAAppendix 4C
30/01/09PRICE SENSITIVE
SLAFinal Call of $0.05 per Contributing Share
21/01/09
SLAFinal Call of $0.05 per Contributing Share
15/01/09PRICE SENSITIVE
SLAAppendix 3Y
12/01/09
SLAAppendix 3Y
08/01/09
SLAEntitlement Issue
02/01/09
SLARetirement of Director
15/12/08
SLANon-Renounceable Pro-Rata Rights Issue
11/12/08
SLAAppendix 3Z
05/12/08
SLAAppendix 3B
03/12/08
SLAResults of Annual General Meeting
01/12/08
SLAPresentation to Annual General Meeting of Shareholders
28/11/08
SLAMiddle Eastern and Asian Distribution Agreements
26/11/08PRICE SENSITIVE
SLANon-Renounceable Pro-Rata Rights Issue - Revised Terms
25/11/08PRICE SENSITIVE
SLAAppendix 3Y
25/11/08
refresh Created with Sketch. REFRESH
 

Top Stories

Tambourah chases gold veins and mineralisation extension with drilling

Tambourah Metals Ltd has discovered two high-grade gold veins through a diamond drilling program in Western Australia
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.